Cytokinetics CYTK
NASDAQ CYTK
$55.42 +0.28 (+0.51%)
As of: Nov 10, 2026 · 2:16 PM EST

Cytokinetics (CYTK) Restructuring Costs (2012)

Updated

Cytokinetics (CYTK) recorded Restructuring Costs of -$56,000 in FY2012, compared with $1.19 million in FY2011.

Analysis

Cytokinetics (CYTK) Restructuring Costs (2012) Analysis & Trends

  • Per Business Quant data, CYTK's Restructuring Costs was $1.19 million in FY2011 and -$23,000 in FY2009.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Cytokinetics 7.81 Bn 3.81 Bn 47.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2012 -2,000.00
Jun 30, 2012 -13,000.00
Mar 31, 2012 -41,000.00
API Access

Cytokinetics Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=CYTK&period=max&api_key=YOUR_API_KEY